Aprotinin Fifteen Years Later

Abstract

Aprotinin, the broad-based bovine serine protease inhibitor, was first used as an antidote against the harmful proteases released through complement-induced neutrophil activation in the early 1980s. Since then, the safety and efficacy of aprotinin have been debated. Even now, fifteen years later, aprotinin's precise mechanism of action and clear indications for use have not been defined. This article discusses what aprotinin is, its role in the contact system of blood, how it improves hemostasis, the effect of temperature on it, its use in clinical practice, and which patients should receive it. The article concludes that aprotinin's hemostatic effects are useful in patients who are at increased risk from bleeding, but that it should not be considered a substitute for surgical skill. Early claims of absolute safety were premature. Risks between high- and low-dose regimens vary significantly, and more study is required. Alternatives to aprotinin such as the less expensive antifibrinolytic agent tranexamic acid are now available, but they also require additional study.